Structure-based design of PDK1 inhibitors
Anders Poulsen1, Stéphanie Blanchard, Chang Kai Soh
1S BIO Pte Ltd, 1 Science Park Road, #05-09 The Capricorn, Singapore Science Park II, Singapore 117528, Singapore. anders@colours.dk
Bioorganic & Medicinal Chemistry Letters
|November 29, 2011
Summary
Researchers optimized a kinase inhibitor by modifying its core structure and linker. This led to improved binding and properties, enhancing its potential as a therapeutic agent.
Area of Science:
- Medicinal Chemistry
- Chemical Biology
- Drug Discovery
Background:
- Macrocyclic inhibitors targeting kinases like CDK, Flt3, and JAK2 were investigated.
- A specific inhibitor exhibited moderate activity against 3-phosphoinositide-dependent protein kinase-1 (PDK1).
Purpose of the Study:
- To enhance the potency and properties of a macrocyclic kinase inhibitor.
- To explore structural modifications for improved binding and physicochemical characteristics.
Main Methods:
- Computational docking into a PDK1 X-ray structure to guide medicinal chemistry efforts.
- Systematic structural modifications, including pyrimidine-to-purine substitution and macrocyclic linker deletion.
- Introduction of an amino-amide solubility tag to improve drug-like properties.
Main Results:
- Structural analysis suggested replacing the pyrimidine with a purine ring could enhance hydrophobic interactions and hydrogen bonding with PDK1.
- Deletion of the macrocyclic linker facilitated faster optimization of aromatic substituents.
- The modified inhibitor demonstrated improved binding affinity and favorable physicochemical properties, maintaining ligand efficiency.
Conclusions:
- Structural modifications, including purine substitution and linker deletion, significantly improved the kinase inhibitor's profile.
- The optimized inhibitor shows promise for further development as a therapeutic agent targeting relevant kinases.
- This study highlights the successful application of structure-based drug design and iterative optimization in medicinal chemistry.
More Related Videos
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:04Protein-protein Interfaces
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a polypeptide...
02:54Protein Kinases and Phosphatases
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...